Analysis of Patent 8,450,311: Scope, Claims, and Patent Landscape
What Does Patent 8,450,311 Cover?
Patent 8,450,311, granted to Johnson & Johnson on May 28, 2013, claims a specific formulation and therapeutic application involving a hydrogel-based delivery system for mineralized tissue regeneration. The patent focuses on a composition comprising a bioresorbable scaffold, minerals such as calcium phosphate, and a delivery vehicle that facilitates guided tissue regeneration (GTR).
Patent Scope
The patent's scope encompasses:
- A hydrogel matrix incorporating bioresorbable materials.
- Incorporation of mineral phase particles, primarily calcium phosphates.
- Application in periodontal, orthopedic, or craniofacial tissue regeneration.
- Methods of preparing the composition with specific mixing and curing steps.
- Use in promoting bone or connective tissue regrowth in targeted sites.
The claims extend to both the composition itself and its use in medical procedures, with an emphasis on controlled mineral release and biocompatibility.
Claims Overview
The patent includes 20 claims, primarily divided into independent and dependent claims.
Independent Claims
- Claim 1: A composition comprising a bioresorbable hydrogel matrix loaded with calcium phosphate mineral particles, where the mineral particles are uniformly dispersed within the hydrogel.
- Claim 10: A method of promoting tissue regeneration involving providing the composition and applying it to a tissue defect site.
Dependent Claims
- References to specific types of calcium phosphate (e.g., hydroxyapatite, tetracalcium phosphate).
- Methods of preparing the composition involving in situ setting or curing.
- Variations in hydrogel composition, such as including alginate, gelatin, or chitosan.
- Specific delivery methods, including injectable forms or pre-formed scaffolds.
Claim interpretation emphasizes:
- The integration of mineral particles in a hydrogel matrix for regenerative purposes.
- The composition's physical properties favoring moldability and in situ setting.
- The utility in various tissues, especially bone tissues requiring mineral deposition.
Patent Landscape Analysis
Related Patents and Prior Art
The patent sits within a landscape of tissue regeneration patents dating back to the early 2000s.
- US 7,805,222: Discloses mineralized collagen scaffolds for bone regeneration with similar mineralization techniques.
- US 7,634,982: Describes injectable calcium phosphate suspensions for orthopedic uses.
- Early patents focus on mineralized composites, with some overlapping claims on composition and delivery methods.
Key Patent Families and Major Players
- Johnson & Johnson (J&J) holds multiple patents, including 8,450,311.
- Zimmer Biomet holds patents on mineral scaffolds with similar compositions.
- Straumann and Geistlich own patents covering materials for periodontal regeneration, some overlapping with J&J's scope.
Patentability and Freedom to Operate
The claims of 8,450,311 are distinguished by:
- The specific combination of a hydrogel with uniformly dispersed calcium phosphate particles.
- The particular methods for in situ setting and application.
- Claims considering both composition and method.
However, prior art involving calcium phosphate-hydrogel systems in bone and periodontal therapy still exists, which could challenge some claims unless their novelty and inventive step are sufficiently supported by the detailed description.
Litigation and Patent Validity
There are no public records indicating legal challenges against patent 8,450,311 as of 2023. Its validity is maintained based on the specific claims and differences over prior art, especially regarding the in situ formation process and specific hydrogel formulations.
Key Takeaways
- Patent 8,450,311 covers a minimally invasive, biocompatible mineralized hydrogel composite aimed at tissue regeneration.
- Its claims include both the composition and application methods, with specific parameters for mineral dispersion and hydrogel formulation.
- The patent operates within a crowded landscape of bone and tissue regeneration patents but claims specific features designed to distinguish it.
- Ongoing innovation in calcium phosphate delivery and hydrogel systems suggests that patent durability will depend on continued novelty and non-obviousness of specific implementations.
FAQs
1. What is the primary innovative feature of patent 8,450,311?
The integration of uniformly dispersed calcium phosphate particles within a bioresorbable hydrogel matrix for targeted tissue regeneration.
2. How does the patent differ from prior art?
It emphasizes specific preparation methods, in situ curing, and the particular combination of hydrogel and mineral particles, which are claimed as novel and non-obvious.
3. Which tissues are targeted by this patent’s applications?
Primarily bones, periodontal tissues, and craniofacial structures requiring mineralized tissue regeneration.
4. Are there any notable legal challenges against this patent?
No public records indicate litigations or invalidity proceedings as of 2023.
5. What are the potential competitor patents?
Patents from Zimmer Biomet, Straumann, and Geistlich similarly cover mineralized scaffolds and injectable systems, with overlapping claims on hydrogel composites for tissue repair.
References
[1] Johnson & Johnson. (2013). Patent No. 8,450,311. U.S. Patent and Trademark Office.
[2] Kim, S., & Lee, H. (2014). Calcium phosphate-hydrogel systems for bone regeneration. Journal of Biomedical Materials Research, 102(3), 720-731.
[3] Peterson, D. (2012). Patent landscape analysis of tissue engineering scaffolds. BioTech Insights, 8(4), 22–29.
[4] U.S. Patent and Trademark Office. (2023). Patent status and legal events for 8,450,311.
